Search Results
Your search for this matches 25372 pages
Showing 20651 - 20700Expert Point of View: Kent Osborne, MD
“Over time, we have been doing less radiation and less surgery to control local disease, mainly because our systemic therapies (endocrine therapy, aromatase inhibitors, and chemotherapy) are killing cancer cells and obviating the need for local therapy. This study is likely to be...
Can Postoperative Radiotherapy Be Avoided in Older Women With Early Breast Cancer and High Estrogen Receptor Expression?
A more conservative approach that avoids radiation therapy seems to be a reasonable option for a subgroup of older women with hormone receptor–positive breast cancer at low risk of recurrence. Overall outcomes were similar with or without radiation in older women with hormone receptor–positive...
Expert Point of View: Debu Tripathy, MD
Debu Tripathy, MD, Professor of Medicine, Co-Leader of the Women’s Cancer Program, and the Priscilla and Art Ulene Chair in Women’s Cancer at the University of Southern California Norris Cancer Center, Los Angeles, commented on the APT study for The ASCO Post. “In treating early-stage...
HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen
There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...
Seven Studies at SABCS Make Dr. Jame Abraham's List of 'Practice-Changing' Talks
From December 10 to 14, the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine once again hosted the San Antonio Breast Cancer Symposium (SABCS), presenting...
Philips Receives FDA Clearance for Spectral Breast Density Measurement Application
Royal Philips has announced that that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Spectral Breast Density Management Application for its MicroDose SI full-field digital mammography system. The application is the first spectral breast density measurement ...
Addressing the Challenges of an Aging Population
We have an aging population, which is a good thing since people are living longer. [But] cancer is a disease that tends to occur most frequently in older people, so the combination of those two events will lead to many more older people with cancer, a larger cancer population in general, and a...
Evaluating and Screening Geriatric Patients for Treatment
One of the key questions in geriatric oncology is: How can we use all of the work geriatricians have done over the years in general geriatrics and apply that to the field of oncology? One-quarter to one-third of us are going to develop cancer throughout our lifetime, and half of the time it is...
International Society of Geriatric Oncology Meeting Explores Multidisciplinary, Tailored Treatment of Older Patients With Cancer
The annual meeting of the International Society of Geriatric Oncology (SIOG, www.siog.org) was held in Copenhagen from October 24 to 26. The theme of the meeting was the “Multidisciplinary Approach Towards Personalized Treatments.” The Society, which was founded in 2000, is a multidisciplinary...
Expert Point of View: Carlos L. Arteaga, MD and David Cameron, MD, MRCP
After the IBIS-II presentation at the San Antonio Breast Cancer Symposium, Carlos L. Arteaga, MD, of Vanderbilt Ingram Cancer Center, Nashville, noted that women at high risk are afraid of developing breast cancer and that pharmacologic intervention may allay their anxiety. “Dr. Cuzick’s study...
Anastrozole Halves Risk of First Breast Cancer in High-Risk Postmenopausal Women
Five years of treatment with anastrozole reduced the risk of breast cancer by 53% in postmenopausal women at high risk for developing the disease, according to an analysis of the International Breast Cancer Intervention Study (IBIS)-II trial. Anastrozole reduced the risk of estrogen...
Expert Point of View: Prashant Kapoor, MD
At the recent American Society of Hematology Annual Meeting, Prashant Kapoor, MD, Assistant Professor of Hematology at Mayo Clinic, Rochester, Minnesota, agreed that CTL019 is a promising, exciting, and novel approach to treating patients with advanced B-cell hematologic malignancies. “Although...
Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas
Reports have been trickling in from centers conducting research on the use of chimeric antigen receptor–modified T cells (CAR-T) in hematologic cancer, and the news is encouraging. When directed against CD19, such personalized therapeutic T cells are known as CTL019, and small pilot trials of this...
Expert Point of View: Peter Ravdin, MD
These results are striking in postmenopausal women. The survival advantage in postmenopausal women leaves no room for interpretation. If survival is improved, you have done something good,” stated Peter Ravdin, MD, commenting on the EBCTCG meta-analysis presented at the San Antonio Breast Cancer...
Adjuvant Bisphosphonates in Early Breast Cancer: Practice-Changing Findings?
Adjuvant use of bisphosphonates reduced the risk of bone recurrence by 34% and the risk of breast cancer death by 17% in postmenopausal women with early breast cancer in a large meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). The potentially...
ASCO's 50th Anniversary and the Road Ahead
As the American Society of Clinical Oncology celebrates its 50th anniversary, ASCO’s Chief Executive Officer Allen S. Lichter, MD, FASCO, recently talked with The ASCO Post about the Society’s past, present, and future. Important Milestone What are your thoughts about ASCO’s origins and its 50th...
Expert Point of View: Joseph R. Mikhael, MD
These are exciting data from the head-to-head phase III comparison of MPT [melphalan, prednisone, and thalidomide (Thalomid)], a globally accepted standard of care, to the novel combination of lenalidomide/low-dose dexamethasone in newly diagnosed multiple myeloma patients ineligible for...
Continuous Lenalidomide/Low-Dose Dexamethasone: A New Option for Older Patients With Newly Diagnosed Myeloma
First-line treatment of newly diagnosed multiple myeloma using the Rd regimen (continuous lenalidomide [Revlimid] plus low-dose dexamethasone) was superior to standard triplet treatment with MPT (melphalan, prednisone, and thalidomide [Thalomid]) for 72 weeks, according to initial results of the...
Artemis Project® for a Preventive Breast Cancer Vaccine
I read with interest the article, “Breast Cancer Vaccines for Primary Prevention Move Toward Clinical Use,” which appeared in the December 15th issue of The ASCO Post (page 28). However, information presented regarding the National Breast Cancer Coalition’s (NBCC’s) Artemis Project for a breast...
Leukemia Pioneer John M. Goldman, DM, Dies at 75
“He gave his honours to the world again,his blessed part to heaven, and slept in peace.” —William Shakespeare, Henry VIII In 1971, John M. Goldman, DM, FRCP, FRCPath, FMedSci, began research in chronic myeloid leukemia (CML), a uniformly fatal disease at the time. Over the ensuing decades, Dr....
Final Overall Survival Data Show Better Results With Higher Dose of Fulvestrant
Among patients with locally advanced or metastatic estrogen receptor–positive breast cancer, fulvestrant (Faslodex) given at 500 mg “is associated with a 19% reduction in risk of death and a 4.1-month difference in median overall survival compared with fulvestrant 250 mg,” according to final...
Expect Questions, and Some Reluctance, About Getting a Flu Shot
People with weakened immune systems due to diseases like cancer are at increased risk of severe complications from the flu virus and should get flu shots annually. The Centers for Disease Control and Prevention (CDC) strongly encourages this practice, and most oncologists would recommend that for...
Cancer Patients Are at Increased Risk of Complications From the Flu and Should Receive Flu Shots, but Not the Nasal Spray
Widespread influenza activity continues to be reported by the Centers for Disease Control and Prevention (CDC), with a recent increase in flu-related hospitalizations.1,2 Patients with cancer are at increased risk from flu complications and should receive the flu shot, but not the flu nasal spray...
Grant to Develop Website and Mobile App to Track Radiation Therapy Toxicity Awarded to Radiation Oncology Resident
The Radiation Oncology Institute has selected Malolan S. Rajagopalan, MD, a radiation oncology resident at the University of Pittsburgh Cancer Institute, to receive a $20,000 grant for a project to compile best practices regarding the management of radiation therapy toxicity. Dr. Rajagopalan’s...
An Overview of the REGAL Trial and Anti-VEGF Therapies in Recurrent Glioblastoma
As published in the Journal of Clinical Oncology by Batchelor and colleagues1 and reviewed in a recent issue of The ASCO Post (November 15, 2013, page 106), the REGAL trial was a randomized, phase III, placebo-controlled, partially blinded trial evaluating the efficacy of cediranib, an...
Major Cancer Milestones in History, From ASCO’s CancerProgress.Net
To help tell the story of progress against cancer, ASCO launched CancerProgress.Net in 2011. The site is intended as a resource for media, policymakers, oncologists, advocates, and the public. One central feature of the site is an interactive timeline of major milestones in cancer treatment,...
Gary Lyman, MD, Joins Scott Ramsey, MD, PhD, in Co-Leading Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson
The Hutchinson Institute for Cancer Outcomes Research (HICOR) has named Gary Lyman, MD, MPH, the Institute’s Co-Director with Scott Ramsey, MD, PhD, an internist and health-care economist, and a member of the Cancer Prevention Program in the Public Health Sciences Division at Fred Hutchinson Cancer ...
Reports From the IPOS/AORTIC Travel Scholars
Eight individuals were awarded travel scholarships allowing them to attend the IPOS/AORTIC Program (International Psycho-Oncology Society/African Organization for Research and Training in Cancer) and share their experiences and efforts toward improving the psychosocial care of patients with cancer...
Surgeon General’s New Report Attributes Smoking as Cause of Death in More Than 20 Million Americans Over Past 50 Years
According to a new Surgeon General’s report issued last month, more than 20 million Americans have died from smoking over the past 50 years. The new report concludes that cigarette smoking kills nearly half a million Americans a year, with an additional 16 million suffering from smoking-related...
50th Anniversary of the First U.S. Surgeon General’s Report on Smoking and Health
“When the first Surgeon General’s Report was released in 1964, more than half of American men and over a third of women smoked and lung cancer had gone from an obscure disease to a leading cause of death. In issuing this pioneering report summarizing the known health risks of smoking, our nation’s...
FDA Approves Combination Therapy for Unresectable or Metastatic Melanoma With BRAF V600E/K Mutations
The U.S. Food and Drug Administration (FDA) has approved trametinib (Mekinist) for use in combination with dabrafenib (Tafinlar) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved...
Expanded Options for Age and Donor Sources for Transplant
Although many oncologists consider matched sibling donors as the best source of grafts for hematopoietic cell transplantation, two separate studies presented at the recent American Society of Hematology Annual Meeting support the use of alternative donor grafts for patients with lymphoma and acute...
ASCO Proposes New Framework for Medicare Reimbursement
In the fifth installment of the Physician Payment Reform Educational Series, ASCO presents an alternative for oncology reimbursement that recognizes and rewards high-quality, high-value care for patients with cancer. ASCO hopes this proposal will spark conversation within the oncology community and ...
Cancer.Net’s Newest Resource—the Cancer.Net Blog
Starting this year, Cancer.Net added a new interactive blog to its list of resources. Using the blog, Cancer.Net will be able to share information in a more timely manner and respond to current events, including breaking news about cancer advances and other topics important to people affected by...
ASCO Cosponsors Inaugural Palliative Care in Oncology Symposium
In October, ASCO will cosponsor the inaugural Palliative Care in Oncology Symposium with the American Academy of Hospice and Palliative Medicine (AAHPM), the American Society for Radiation Oncology (ASTRO), and the Multinational Association of Supportive Care in Cancer (MASCC). The Symposium is...
Conquer Cancer Foundation Funds Research in Low- and Middle-Income Countries for the First Time
The Conquer Cancer Foundation of the American Society of Clinical Oncology has announced the four recipients of the inaugural 2014 International Innovation Grant, which is a new program that underscores the Foundation’s continued commitment to improving the care of patients worldwide. The 1-year...
ASCO Member Helps to Strengthen Cancer Care Internationally Through Philanthropy and Volunteer Service
Ian F. Tannock, MD, PhD, DSc, FASCO, Professor of Medical Oncology at Princess Margaret Hospital and University of Toronto, has long been an advocate for ASCO as a truly global society and a leader in cancer care worldwide. It’s something he encouraged during his time on ASCO’s Board of Directors,...
IPOS/AORTIC Conference Aims to Bring Comprehensive Care to Patients in Africa
More than 1,000 scientists from 66 countries, including 32 of the 52 African countries, attended the African Organization for Research and Training in Cancer (AORTIC) 9th International Conference on Cancer in Africa, held this past November in Durban, South Africa. The theme of the 2013 meeting was ...
ASCO President Issues Statement on Major Decline in Lung Cancer
Editor’s note: The Centers for Disease Control and Prevention (CDC) recently issued a report on lung cancer incidence trends in the United States.1 According to the report, incidence rates for lung cancer have decreased between 2005 and 2009, the period evaluated. Lung cancer incidence has...
Expert Point of View: Matthew Ellis, MB, PhD
Matthew Ellis, MB, PhD, Professor of Medicine and the Anheuser-Busch Chair in Medical Oncology at Washington University School of Medicine, St. Louis, commented for The ASCO Post on the emerging field of research on drugging PI3K mutations. Critical Mechanisms “Multiple somatic lesions in breast...
Drugging PI3K in Breast Cancer: Findings From SABCS 2013
Components of the phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway are deregulated in many human cancers, with about 30% of breast cancers harboring PIK3CA gene mutations. Emerging research shows that these mutations may render estrogen receptor alpha-positive tumors ...
Lung Cancer Screening Facts
The U.S. Preventive Services Task Force has posted a supplemental fact sheet for clinicians on its final recommendation statement on screening for lung cancer.1 This resource is meant to help health-care professionals talk about lung cancer screening with their patients and determine if screening...
Common Mutations May Impact Neoadjuvant Treatment Outcomes in Breast Cancer
Emerging research is suggesting that outcomes from neoadjuvant chemotherapy may be correlated with two genetic mutations that are common in breast cancer—PIK3CA and TP53. Their presence may affect response to treatment, and mutational shift after treatment may affect survival, according to studies...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz, MD, PhD, Chair of the Non-Hodgkin Lymphoma Guideline Panel of the National Comprehensive Cancer Network (NCCN) and former Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center, New York, commented on the study by Yamshon et al for The ASCO Post. He said the...
‘R-Squared’ Lymphoma Treatment: Possible Markers of Response Identified
A correlative analysis of a study evaluating lenalidomide (Revlimid) plus rituximab (Rituxan) in patients with indolent non-Hodgkin lymphoma found that increases in the levels of several cytokines correlated with response to treatment. The study by investigators from the University of California...
Lenalidomide/Rituximab Doublet a Potential Front-Line Treatment in Some Lymphomas
The biologic doublet of lenalidomide (Revlimid) plus rituximab (Rituxan) can achieve high response rates and durable remissions in lymphoma, according to a parade of phase II studies presented at the 2013 American Society of Hematology (ASH) Annual Meeting in New Orleans. The immunomodulatory agent ...
Cancer Genes, Promiscuity, and the National Debt
There is no doubt that this is a halcyon period in oncology. The unraveling of the genome has been tremendously important, and finally has helped us to move treatment selection from an era of rational empiricism to one of refined, molecular prognostication. In the care of breast cancer, the impact...
Expert Point of View: Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, Professor of Medicine and Director of Breast Medical Oncology at Yale University, New Haven, Connecticut, who was the formal discussant of the papers by Sikov et al and Rugo et al, said there is mounting evidence for using carboplatin. He and his own research team have...
Addition of Carboplatin to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Supported by SABCS Studies
The achievement of a pathologic complete response in patients with triple-negative breast cancer was boosted by the addition of carboplatin to a standard neoadjuvant chemotherapy regimen, and by the addition of veliparib, an investigational oral PARP inhibitor, plus carboplatin to a standard...
Role for Reduced-Intensity Conditioning Regimen in AML After Allogeneic Transplantation
Reduced-intensity conditioning and myeloablative-conditioning regimens following allogeneic hematopoietic cell transplantation in children with acute myeloid leukemia (AML) resulted in comparable survival, according to a study published in Blood. The study evaluated 181 patients, 39 treated with...
